Dr. Bahija Jallal is Executive Vice President of AstraZeneca and head of MedImmune, a global biologics research and development organization with locations in Gaithersburg, California and Cambridge, UK. She is a member of the senior executive team at AstraZeneca reporting to the CEO. Dr. Jallal joined MedImmune in March 2006. Dr. Jallal is passionate about leading and shaping MedImmune’s rich pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardio-vascular and metabolic diseases and pain to ultimately develop new medicines for patients. Dr. Jallal is a member of the Board of Directors of the University of Maryland Health Sciences Research Park Corporation, a non-profit organization that manages biomedical research development at the BioPark. She was recently appointed to the Board of Trustees of The Johns Hopkins University. Dr. Jallal has authored over 70 peer-reviewed publications and has over 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science and the Pharmacogenomics Working Group. She serves as a member of the Board of Directors for the Association of Women in Science and an advisory board member of the Healthcare Business Women’s Association. She was named one of FierceBiotech’s "Women in Biotech" and a "Women Who Mean Business" from the Washington Business Journal. In 2013, Dr. Jallal earned the Grace Award from Cancer Research Institute. Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as vice president, drug assessment and development, and successfully established the company’s translational medicine group. Prior to Chiron Corporation, she worked at Sugen, Inc. where she held positions of increasing responsibility leading to senior director, research.  

 Cardio-Vascular, Metabolic Disease, Respiratory and Inflammatory